Dicerna, Actifio Headline Top 10 Third Quarter VC Deals in Massachusetts

10/18/10Follow @gthuang

[Corrected, 9:50 am. See below] The third quarter of 2010 has been in the books for a couple weeks. Time to look back at the top 10 venture capital financings for Boston-area companies from the past three months (July-September). The roundup comes courtesy of the MoneyTree Report, which is prepared each quarter by PricewaterhouseCoopers and the National Venture Capital Association, using data from Thomson Reuters. My colleague Bruce Bigelow wrote up the national quarterly stats, which showed a “new reality” for VC, here.

As usual, biotech and life sciences deals dominated the top-dollar deals in Massachusetts, with Dicerna Pharmaceuticals, Euthymics Bioscience, and Metamark Genetics leading the way with $20 million-plus venture financings. There were a couple of notable tech financings too: data management startup Actifio raising $20 million in separate rounds, and group-buying site BuyWithMe closing $16 million in venture capital to expand its operations. And in cleantech, A123Systems’ energy-storage spinout 24M Technologies made a splash with a $10 million financing round.

Here’s the list of top 10 venture financings for Boston-area companies in the third quarter of 2010 (actually 11 companies because of a three-way tie for ninth place):

Dicerna Pharmaceuticals $24.8M
Euthymics Bioscience $24M
Metamark Genetics $22.1M
Actifio $20M
Rhythm Pharmaceuticals $19M
Good Start Genetics $18M
BuyWithMe $16M
Second Rotation $12M
Anchor Therapeutics $10M
Taligen Therapeutics $10M
24M Technologies $10M

[An earlier version of this story listed Good Start Genetics as closing $15 million during Q3, according to the MoneyTree report. A Good Start representative wrote in to say the company raised its full $18 million Series A in September---Eds.]

Gregory T. Huang is Xconomy's Deputy Editor, National IT Editor, and the Editor of Xconomy Boston. You can e-mail him at gthuang@xconomy.com or call him at 617-252-7323. Follow @gthuang

By posting a comment, you agree to our terms and conditions.